Narrowband-UVB treatment reduces levels of mediators of the Th17 pathway and chemotaxis in psoriatic skin without any concurring effect on mediator levels in serumShow others and affiliations
2022 (English)In: EJD. European journal of dermatology, ISSN 1167-1122, E-ISSN 1952-4013, Vol. 32, no 2, p. 250-259Article in journal (Refereed) Published
Abstract [en]
Background: Narrowband-UVB (NB-UVB) is a common and effective psoriasis treatment. It exerts its effect locally and is therefore a better model for exploring dynamics of serum biomarkers reflecting psoriasis skin disease activity compared to other treatments with systemic uptake. Objectives: To perform an exploratory study to assess potential roles of multiple disease mediators as biomarkers for psoriasis disease activity, and increase understanding of NB-UVB treatment effects in psoriatic skin. Materials & Methods: Patients with plaque psoriasis were sampled (lesional, non-lesional skin, serum) before and after full NB-UVB treatment. Samples were assessed for 78 different mediators using Luminex assays. Correlation networks were analysed to explore interactions between lesional skin mediators before and after NB-UVB treatment. Results: None of the studied serum mediators were significantly affected by NB-UVB treatment after correction for multiple testing. Thirty mediators revealed a significant difference in lesional skin compared to non-lesional skin before treatment including interleukin 23 (IL-23) and C-C motif chemokine ligand 20 (CCL20), but also novel mediators such as angiopoietin-like 4 (ANGPTL4) and pentraxin 3 (PTX3). The levels of 25 mediators in skin decreased significantly, and network analysis revealed markedly reduced cluster formations and correlations after NB-UVB. Conclusion: NB-UVB treatment reduced the concentration of mediators of the Th17 inflammatory pathway and chemotaxis in psoriatic lesional skin, but also affected less studied and novel mediators. Although the treatment affected the levels of a majority of mediators in skin, no corresponding effect was observed in serum, thus challenging the possibility of a serum biomarker reflecting skin disease activity.
Place, publisher, year, edition, pages
JOHN LIBBEY EUROTEXT LTD , 2022. Vol. 32, no 2, p. 250-259
Keywords [en]
psoriasis; ultraviolet therapy; Th17 cells; interleukin 23; chemokines; biomarkers
National Category
Dermatology and Venereal Diseases
Identifiers
URN: urn:nbn:se:liu:diva-190362DOI: 10.1684/ejd.2022.4243ISI: 000852382300011PubMedID: 35866911OAI: oai:DiVA.org:liu-190362DiVA, id: diva2:1716678
Note
Funding Agencies|Psoriasisforbundet; Futurum Academy for Health and Care and Region Skane
2022-12-062022-12-062023-12-28